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Abstract
Background: Circulating trimethylamine-N-oxide (TMAO) 
has been implicated in the development of cardiovascular 
and chronic kidney diseases (CKD). However, while higher 
TMAO levels have been associated with increased risks of 
cardiovascular or renal events in first prospective studies, 
it remained unclear how much plasma TMAO concentra-
tions vary over time.
Methods: We measured fasting plasma levels of TMAO 
and two of its precursors, betaine and choline by LC-MS, 
in two samples of 100 participants of the European Inves-
tigation into Cancer and Nutrition (EPIC)-Heidelberg study 
(age range: 47–80 years, 50% female) that were collected 
1 year apart, and assessed their intra-individual variation 
by Spearman’s correlation coefficients (ρ).
Results: Correlations of metabolite concentrations 
over 1 year were at ρ = 0.29 (p = 0.003) for TMAO, ρ = 0.81 
(p < 0.001) for betaine, and ρ = 0.61 (p < 0.001) for choline. 
Plasma levels of TMAO were not significantly associated 
with food intake, lifestyle factors, or routine biochemistry 
parameters such as C-reactive protein (CRP), low-density 
lipoprotein (LDL)-cholesterol, or creatinine.
Conclusions: In contrast to fasting plasma concentrations 
of betaine and choline, concentrations of TMAO were 
more strongly affected by intra-individual variation over 
1 year in adults from the general population. The modest 
correlation of TMAO levels over time should be considered 
when interpreting associations between TMAO levels and 
disease endpoints.
Keywords: betaine; choline; intra-individual variation; 
TMAO.
Introduction
Trimethylamine-N-oxide (TMAO), a small organic com-
pound, whose plasma concentrations depend on dietary 
factors in interaction with the composition of the gut 
microbiome, is widely discussed as a risk factor and 
potential biomarker of chronic kidney diseases (CKD) and 
cardiovascular diseases (CVD) [1–3].
Experimental models indicate that TMAO induces 
atherosclerosis, possibly via macrophage foam cell for-
mation and effects on cholesterol metabolism [4, 5]. 
Moreover, first prospective studies from the United States 
have shown that plasma concentrations of TMAO and two 
of its precursors, betaine and choline, are predictive of 
major cardiovascular events in high-risk individuals [5–
8], even though these findings were not replicated in two 
recent studies from Denmark [9] and Austria and Switzer-
land [10]. Of note, fish is a major dietary source of TMAO 
and fish consumption has been observed to reduce CVD 
risk [11]. With regard to CKD, it has been proposed that 
TMAO may act as a renal toxin, causing tubulointersti-
tial fibrosis and dysfunction [12]. Alternatively, increased 
plasma TMAO levels could also be related to a patho-
logical release of TMAO from the renal medulla, where it 
may act as an osmolyte and also protect protein integrity 
against denaturants, in kidney disease and to decreased 
excretion of TMAO due to impaired kidney function [12]. 
Notwithstanding conflicting evidence on the biological 
role of TMAO in kidney disease, several studies point 
to worse outcome in CKD patients with higher plasma 
levels of TMAO [10, 12–15]. Two recent prospective studies 
further revealed that plasma concentrations of TMAO in 
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asymptomatic individuals were associated with increased 
risks of  colorectal and prostate cancer over time [16, 
17], while mechanistic links between TMAO and cancer 
remain spurious and some experimental data actually 
point to potential anti-carcinogenic effects of TMAO [12].
The synthesis of TMAO comprises two main steps. 
First, trimethylamine (TMA) is generated from dietary 
l-carnitine, choline, and, to a lesser extent, betaine by 
bacteria in the intestine, where it enters the circulation. 
TMAO is then produced from TMA in the liver by TMA-
oxidizing flavin-containing monooxygenases (FMO) 
[5, 8, 18]. Interestingly, the main sources of TMAO’s major 
precursors l-carnitine and choline are animal foods, 
such as meat, fish, dairy products, and eggs, and it has 
been suggested that increased TMAO levels may under-
lie higher risks of CVD and CKD of individuals with high 
intakes of animal products and particularly red meat [4, 
18, 19]. Besides food intake, the intestinal microbiome 
strongly affects blood concentrations of TMAO, which is 
reflected by the fact that dietary l-carnitine and choline 
challenges in humans lead to increased TMAO levels 
before, but not after the treatment with broad-spectrum 
antibiotics [8,  18]. In addition, it has been shown that 
TMAO levels may be related to specific enterotypes, and 
first taxa that may affect TMAO levels in the human cir-
culation have been identified [18]. At the same time, data 
from a genome-wide association study did not point to a 
strong host genetic influence on circulating TMAO, and 
it has thus been proposed that dietary factors and the 
composition of the gut microbiota are the most important 
determinants of TMAO levels [20].
As dietary habits and the composition of the intestinal 
microbiota may be prone to changes, despite a certain sta-
bility of both factors during adulthood [21, 22], it could be 
speculated that TMAO levels undergo significant changes 
over time. In fact, substantial intra-individual variation 
in circulating TMAO has been observed in a population of 
overweight individuals with type 2 diabetes [23]. However, 
the biological variation of TMAO concentrations in the 
general population is unknown. To address this issue, we 
examined the intra-individual variation of fasting plasma 
levels of TMAO as well as betaine and choline over 1 year 
in 100 adults, who were free of major CVD, kidney diseases 
and cancer at the time of the blood donations. Further, 
as high controlled intakes of animal food that may not be 
entirely representative of individuals’ habitual intakes were 
analyzed in the majority of previous studies on the dietary 
determinants of TMAO, we evaluated associations between 
metabolite concentrations and habitual food intake as 
well as lifestyle factors and routine biochemistry param-
eters. The overall goal of the present study was to assess 
whether TMAO and its precursors may be useful as long-
term  biomarkers in prospective epidemiological studies.
Materials and methods
Study population
The European Investigation into Cancer and Nutrition (EPIC) is a 
cohort study conducted in 23 study sites across 10 Western European 
countries [24]. In Heidelberg, 25,540 individuals (53.3% women) aged 
35–65 years from the local general population entered the EPIC study 
between 1994 and 1998 [25]. Between 2010 and 2013, a sub-study on 
diet, physical activity, and body composition embedded in the EPIC-
Heidelberg study was carried out. Details on this sub-study have 
been given elsewhere [26]. In brief, 798 participants (53.5% women), 
who had been randomly recruited from EPIC-Heidelberg, took part 
in a re-examination 14  years after the baseline of the main study 
(examination 1). The age range of these individuals at examination 
1 was 47–80 years. Data on habitual food intake were collected by 
a validated food frequency questionnaire [27]. Body composition 
was assessed by whole-body magnetic resonance imaging (MRI) 
in a  subset of 613 individuals [28]. All 798 participants provided 
 questionnaire-information on medication use, smoking, alcohol 
intake and socio-economic factors. In addition, study physicians car-
ried out interviews on health status and medication use, and took 
a blood sample. The latter interview and blood draw were repeated 
in a second re-examination that took place 1 year after the first one, 
with 765 out of the initial 798 participants attending (examination 2).
For the present study, a sub-sample of 100 participants of the 
EPIC-Heidelberg sub-study described above was selected. First, only 
participants who had provided a fasting blood sample at both re-
examinations were considered (n = 669, 83.8% of the initial sample). 
Second, considering that clear differences in TMAO levels between 
vegetarians and non-vegetarians have been described [18], all veg-
etarians (n = 25) were selected. Out of the remaining 644 individuals, 
those with MRI data were pre-selected (n = 483), and 75 out of these 
483 individuals were randomly chosen to achieve the target number 
of 100. The study population only included individuals who had not 
been diagnosed with cancer or major renal or CVD at the time of the 
blood draws for the present analyses (see Table 1 for details).
All participants gave written consent prior to participation 
in the initial study and the sub-study, and ethical approvals were 
obtained from the Ethics Committee of the Heidelberg University 
Hospital (Heidelberg, Germany).
Laboratory methods
Blood samples were processed right after the blood draws as plasma, 
serum and peripheral blood mononuclear cells (PBMC) and stored in 
gas phase liquid nitrogen at –185 °C. Blood levels of HbA1c, glucose, 
high density lipoprotein (HDL), low density lipoprotein (LDL), tri-
glycerides, C-reactive protein (CRP), creatinine and leucocytes were 
measured by routine assays at the central laboratory of Heidelberg 
University Hospital (Heidelberg, Germany) right after blood dona-
tion. The estimated glomerular filtration rate (eGFR) was calculated 
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Table 1: Characteristics of the study population.
Men (n = 50) Women (n = 50)
Age, years 64.6 (58.6, 71.4) 63.0 (57.3, 70.8)
Education levela
 Low 7 (14%) 5 (10%)
 Medium 14 (28%) 30 (60%)
 High 29 (58%) 15 (30%)
BMI 26.1 (24.7, 27.5) 24.2 (21.6, 27.7)
Waist circumference, cm 97.2 (94.5, 104.3) 89.3 (79.0, 97.0)
Blood pressure
 Systolic 131.5 (124.5, 138.5) 128.5 (116.5, 141.5)
 Diastolic 80.0 (72.5, 85.5) 75 (70, 82)
Smoking status
 Never 18 (36%) 28 (56%)
 Former 25 (50%) 17 (34%)
 Current 7 (14%) 5 (10%)
Prevalent diseases
 Diabetes 2 (4%) 1 (2%)
 Cancer 0 (0%) 0 (0%)
 Stroke 0 (0%) 0 (0%)
 Myocardial infarction 0 (0%) 0 (0%)
eGFR, mL/min/1.73 m2
  > 90 21 (42%) 20 (40%)
 60–90 27 (54%) 27 (54%)
  < 60 2 (4%) 3 (6%)
Red meat intake, g/day 37.5 (14.0, 70.1) 21.9 (5.0, 34.4)
Processed meat intake, g/day 37.6 (20.8, 57.1) 19.5 (9.4, 33.8)
Fish intake, g/day 18.2 (7.8, 29.8) 13.5 (5.2, 27.2)
Cheese intake, g/day 32.5 (23.5, 44.5) 31.3 (24.0, 51.7)
Milk intake, g/day 91.6 (42.3, 179.9) 107.2 (52.7, 185.4)
Egg intake, g/day 13.3 (5.3, 13.8) 5.4 (1.4, 13.7)
Vegetarians 9 (18%) 17 (34%)
Prebiotics useb 2 (4%) 5 (10%)
Antibiotics usec
 Examination 1 0 1 (2%)
 Examination 2 0 1 (2%)
TMAO, µmol/L
 Examination 1 3.6 (2.9, 4.7) 3.7 (2.6, 4.6)
 Examination 2 4.5 (2.8, 6.0) 3.4 (2.7, 4.7)
Choline, µmol/L
 Examination 1 36.9 (29.0, 46.3) 27.6 (22.3, 34.6)
 Examination 2 37.5 (30.9, 45.3) 29.5 (23.1, 38.0)
Betaine, µmol/L
 Examination 1 11.4 (10.3, 12.7) 10.3 (9.4, 11.5)
 Examination 2 12.1 (11.2, 14.1) 10.7 (9.5, 11.1)
All covariates except antibiotics use and metabolite concentrations from examination 1. Continuous variables: median value (25th percen-
tile, 75th percentile). Categorical variables: number (percentage). aLow, primary school or no formal school degree; medium, secondary or 
technical degree; high, university degree. bWithin the past year before first blood draw. cWithin 7 days before blood draw.
based on creatinine levels using the BIS1 formula [29] for individu-
als aged  ≥ 70  years and the CKD-EPI formula [30] for individuals 
aged  < 70 years. Total adiponectin was measured in stored plasma 
samples in the laboratory of the Division of Cancer Epidemiology at 
the German Cancer Research Center, DKFZ (Heidelberg, Germany) by 
Sandwich ELISA (A68456; Beckman Coulter, Sinsheim, Germany).
For the measurements of TMAO, betaine, and choline, 20-µL 
samples of EDTA-plasma were shipped to the Institute of Clinical 
Chemistry, University Hospital Zurich (Zurich, Switzerland) on dry 
ice, where they were thawed at room temperature. Metabolite lev-
els were quantified by LC-MS, as previously described [10]. In brief, 
360 µL of an internal standard mixture containing TMAO-d9, betaine-
d3 and choline-d9 at 1 µmol/L were added. After vortexing and 
centrifugation at 11,700 × g for 10  min at 4 °C, the supernatant was 
analyzed. Separation was achieved on an Accucore HILIC column 
(50 × 2.1 mm, 2.6 µm particle size, Thermo Fisher Scientific, Reinach, 
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Switzerland) under acidic conditions. As mass spectrometer, a Q 
Exactive hybrid instrument (Thermo Fisher Scientific) was used, that 
acquired chromatograms in positive heated electrospray ioniza-
tion fullscan mode at a resolution of 70,000 full width at half maxi-
mum (FWHM). Extracted ion chromatograms with mass windows of 
10 ppm of TMAO, betaine, choline and the respective internal stand-
ards were used for quantification. Calibration ranges were 0.54–71.9 
µmol/L for TMAO, 5.07–162 µmol/L for betaine and 1.92–61.5 µmol/L 
for choline. Between-day imprecision was  < 10.6% for TMAO,  < 6.25% 
for betaine and  < 6.11% for choline, and between-day accuracy was 
92.4% for TMAO, 99.5% for betaine and 97.1% for choline.
Statistical analyses
The biological reproducibility of metabolite concentrations over 1 
year was assessed by Spearman’s correlation coefficients (ρ) adjust-
ing for age and sex, and by scatter plots. As intra-class coefficients 
of variation (ICC) were reported in previous reproducibility studies, 
we further calculated ICCs (ratio of between-person variance divided 
by the sum of between-person variance and within-person variance) 
based on log-transformed metabolite concentrations for comparison 
purposes. Geometric means (95% confidence intervals) of metabolite 
levels across categories of background factors such as age group, 
sex, our smoking status were obtained. Correlations matrices were 
created to visualize correlations of TMAO, betaine, and choline with 
routine biochemistry parameters.
Results
Intra-individual variation of metabolite 
concentrations
Characteristics of the study population that comprised 50 
women (median age: 63.0 years) and 50 men (median age: 
64.6 years) are shown in Table 1. Median fasting plasma 
concentrations of TMAO, betaine, and choline in women 
were 3.7, 10.3, and 27.6 µmol/L at the first examination 
and 3.4, 10.7, and 29.5 µmol/L after 1 year. In men, median 
levels of TMAO, betaine, and choline were 3.6, 11.4, and 
36.9 µmol/L at the first examination and 4.5, 12.1, and 
37.5 µmol/L after 1 year. Individual metabolite concentra-
tions from two blood samples taken at the two examina-
tions that were carried out 1 year apart are depicted in 
Figure  1. Unadjusted Spearman’s coefficients for corre-
lations of TMAO, betaine, and choline levels over 1 year 
(see Table 2) were 0.29 (p = 0.003), 0.81 (p < 0.001), and 
0.61 (p < 0.001). After adjustment for age and sex, the esti-
mates were 0.28, 0.76, and 0.52. Unadjusted ICCs (TMAO: 
0.22, betaine: 0.76, and choline: 0.63) were slightly lower 
than unadjusted Spearman’s coefficients. The exclu-
sion of high TMAO values ( > 10 µmol/L) did not lead to 
clear improvements of the correlation over time, with 
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Figure 1: Scatter plots of metabolite levels.
(A) TMAO, (B) betaine, (C) choline.
a Spearman’s coefficient of 0.37 and an ICC of 0.39. Cor-
relations remained virtually unchanged when excluding 
individuals (n = 5) with eGFR values  < 60 mL/min/1.73 m2 
or when adjusting for eGFR values (data not shown). The 
highest within-person variation (CVI) was observed for 
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Table 2: Correlations of metabolite concentrations over 1 year.
Spearman’s ρ ICCa Coefficient of 
within-person 
variation (CVI),  %
Coefficient of 
between-person 
variation (CVG), %
Unadjusted Adjusted for 
age and sex
Betaine 0.81 0.76 0.76 17.0 30.5
Choline 0.61 0.52 0.63 11.5 15.1
TMAO 0.29 0.28 0.22 46.7 24.7
aIntraclass-correlation coefficient calculated as the ratio of between-person variance divided by the sum of between-person variance and 
within-person variance.
TMAO (46.7%), whereas within-person coefficients of vari-
ation were 17.0% and 11.5% for betaine and choline.
Correlates of metabolite concentrations
Cross-sectional associations between metabolite concen-
trations and epidemiological covariates are presented in 
Table 3. TMAO levels were significantly higher in users 
of prebiotic medication compared to non-users. By con-
trast, plasma choline and betaine were significantly lower 
in users of prebiotics. No significant differences in TMAO 
levels across strata of other covariates were observed. 
Concentrations of choline and betaine were significantly 
higher in fasting plasma of males, older study participants 
and individuals with higher intakes of processed meat.
Correlations between TMAO, its precursors and 
routine clinical biochemistry parameters are depicted in 
Supplemental Figure 1. None of the routine parameters 
showed correlations with TMAO, choline, and betaine at 
Spearman’s coefficients of at least 0.3, with the excep-
tion of creatinine, which was positively correlated with 
betaine (ρ = 0.27 at examination 1 and ρ = 0.40 at exami-
nation 2) and choline (ρ = 0.39 and ρ = 0.50). There were 
modest correlations between betaine and choline levels at 
both examinations (ρ = 0.55 and ρ = 0.47). No strong corre-
lations between concentrations of these two metabolites 
with concentrations of TMAO were observed.
Discussion
We evaluated the biological reproducibility of plasma 
levels of TMAO over 1 year in adults aged 64  years on 
average who had not been diagnosed with cancer or major 
renal and CVD. Compared to betaine and choline concen-
trations, which showed intra-individual correlations of 
ρ = 0.81 and ρ = 0.61 over 1 year, the correlation of TMAO 
concentrations was lower (ρ = 0.29). The within-person 
variation of TMAO levels (CVI = 46.7%) was greater than 
the between-person variation (CVG = 24.7%), again in 
contrast to betaine (CVI = 17.0%, CVG = 30.5%) and choline 
(CVI = 11.5%, CVG = 15.1%). No clear associations between 
TMAO concentrations and epidemiological covariates 
such as habitual meat intake, obesity, or smoking status 
were observed. TMAO levels were not related to levels 
of routine biomarkers of lipid and glucose metabolism, 
inflammation or renal function.
We are aware of only one previous study, in which 
intra-individual variation in TMAO levels over time has 
been evaluated. In the Diabetes Excess Weight Loss 
(DEWL) study, 243 overweight type 2 diabetic patients 
(median age: 60  years) provided fasting blood samples 
four times at 6-month intervals over 2  years [23]. While 
reliability coefficients for betaine (0.75) and choline (0.67) 
based on concentrations from all four blood samples 
pointed to good biological reproducibility over time, 
plasma TMAO levels were affected by substantial intra-
individual variation, with a reliability coefficient of 0.17. 
The within-person variation in the DEWL trial was higher 
for TMAO (63.3%) than for betaine (14.9%) and choline 
(14.4%), which is consistent with the within-person CVs 
of 46.7%, 17.0%, and 11.5% observed for TMAO, betaine 
and choline in the present study. Intra-individual vari-
ation over time of choline and betaine, but not TMAO 
has further been assessed in participants of the Nurses’ 
Health Study (NHS) and the Western Norway B Vitamin 
Intervention Trial (WENBIT) [31]. Spearman’s correlations 
for betaine (ρ = 0.64) and choline (ρ = 0.33) were slightly 
worse in NHS compared to our study (ρ = 0.81 and ρ = 0.61, 
respectively), even though the duration of 1–2  years 
between blood draws was longer in the NHS than in EPIC-
Heidelberg (1 year) [31]. In the WENBIT study, intra-class 
correlations based on four samples taken over 38 months 
were at 0.65 for betaine and 0.45 for choline [31]. Given the 
longer time periods between blood draws in the NHS and 
WENBIT, these results and the results of the above men-
tioned DEWL trial on choline and betaine are consistent 
with ours.
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Table 3: Geometric means (95% CIs) of metabolite concentrations.
TMAO, µmol/L Betaine, µmol/L Choline, µmol/L
Ø (95% CI) p-Value Ø (95% CI) p-Value Ø (95% CI) p-Value
Sex
 Female 3.9 (3.4, 4.5) 28.1 (25.9, 30.6) 10.3 (9.8, 10.8)
 Male 3.7 (3.2, 4.3) 0.56 36.1 (33.2, 39.3)  < 0.001 11.5 (11.0, 12.1)  < 0.001
Age
  < 60 years 3.7 (3.2, 4.4) 31.21 (28.3, 34.4) 10.84 (10.3, 11.4)
 60–69.9 years 3.5 (2.9, 4.1) 28.88 (26.1, 31.9) 10.18 (9.6, 10.7)
  ≥ 70 years 4.4 (3.7, 5.2) 0.37 36.51 (32.8, 40.6) 0.027 11.80 (11.1, 12.5) 0.048
BMI
  < 25 3.9 (3.4, 4.6) 34.0 (31.0, 37.2) 10.8 (10.3, 11.4)
 25–29.9 3.7 (3.2, 4.3) 30.2 (27.6, 33.1) 10.8 (10.3, 11.4)
  ≥ 30 3.8 (2.7, 5.3) 0.71 30.4 (25.0, 37.0) 0.19 11.6 (10.4, 13.0) 0.62
Smoking status
 Never 3.4 (2.9, 3.9) 33.7 (30.9, 36.7) 11.1 (10.5, 11.6)
 Former 4.2 (3.6, 4.9) 31.5 (28.8, 34.5) 10.6 (10.1, 11.2)
 Current 4.3 (3.2, 5.7) 0.10 26.7 (22.6, 31.7) 0.06 11.2 (10.2, 12.3) 0.46
Prebiotics use
 No 3.7 (3.3, 4.1) 32.5 (30.6, 34.5) 11.0 (10.7, 11.4)
 Yes 5.7 (3.9, 8.3) 0.029 24.5 (19.6, 30.7) 0.019 9.2 (8.2, 10.5) 0.008
Vegetarian diet
 No 3.9 (3.5, 4.4) 32.0 (29.8, 34.3) 11.0 (10.5, 11.4)
 Yes 3.6 (3.0, 4.4) 0.57 31.5 (28.0, 35.5) 0.83 10.7 (10.0, 11.4) 0.52
Processed meat intake
 Lowest quartile 3.7 (3.0, 4.5) 31.0 (27.5, 34.9) 10.8 (10.1, 11.6)
 Highest quartile 4.1 (3.3, 5.1) 0.44 35.6 (31.4, 40.3) 0.018 11.3 (10.6, 12.2) 0.033
Red meat intake
 Lowest quartile 3.7 (3.0, 4.6) 32.0 (28.2, 36.2) 10.8 (10.1, 11.6)
 Highest quartile 3.9 (3.2, 4.8) 0.61 31.5 (27.8, 35.6) 0.46 11.2 (10.4, 12.0) 0.06
Fish intake
 Lowest quartile 3.7 (3.0, 4.5) 32.6 (28.8, 36.9) 10.8 (10.1, 11.5)
 Highest quartile 3.9 (3.2, 4.8) 0.90 31.1 (27.5, 35.2) 0.70 10.6 (9.9, 11.4) 0.69
Cheese intake
 Lowest quartile 3.6 (3.0, 4.4) 33.4 (29.7, 37.4) 11.1 (10.3, 11.8)
 Highest quartile 4.0 (3.3, 4.9) 0.98 28.0 (24.9, 31.4) 0.88 10.5 (9.8, 11.2) 0.84
Milk intake
 Lowest quartile 3.8 (3.1, 4.7) 31.1 (27.5, 35.2) 10.8 (10.1, 11.5)
 Highest quartile 3.9 (3.2, 4.8) 0.32 30.7 (27.2, 34.7) 0.62 10.6 (9.9, 11.3) 0.56
Egg intake
 Lowest quartile 3.9 (3.2, 4.8) 32.8 (29.0, 37.0) 11.0 (10.3, 11.8)
 Highest quartile 3.8 (2.7, 5.3) 0.62 33.2 (27.1, 40.6) 0.94 11.0 (9.8, 12.3) 0.73
Geometric means adjusted for age and sex. p-Values from trend tests across categories obtained by linear regression models. All results 
based on the first examination and blood draw of the EPIC Heidelberg sub-study.
Surprisingly, our study showed no associations 
between TMAO and the consumption of animal food, 
which are the main source of TMAO’s precursors 
l- carnitine and choline. With regard to fish, our popu-
lation had a rather low average habitual intake, which 
may be the reason for the lack of association with TMAO 
levels. Habitual intakes of other animal products in our 
population were still lower than the high intakes of eggs 
and steak for example that have been demonstrated to 
cause increases in TMAO levels in previous intervention 
trials under controlled conditions [18, 32]. This notion 
is supported by recent results from the Second Bavarian 
Food Consumption Survey (BVS II) [33] that did not point 
to strong associations between habitual intake of animal 
foods and TMAO concentrations overall, even though 
slightly higher TMAO levels were observed in individuals 
with higher milk intake. The finding of higher levels of 
TMAO and lower levels of betaine and choline in users 
of prebiotics in the present study was unexpected and in 
contrast to previous studies [34, 35]. However, it must be 
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noted that only 7% of our participants reported to have 
used prebiotics, and no further details on duration and 
frequency of intake were available.
Contrary to previous studies [10, 36], the EPIC- 
Heidelberg study showed no associations between TMAO 
and creatinine or the eGFR. Potentially, this finding may be 
related to the fact that associations between TMAO levels 
and kidney function were reported from studies in high-
risk populations, whereas the individuals in our study were 
free of major chronic diseases. Actually, only a few of our 
study participants had eGFR values  < 60 mL/min/1.73 m2, 
at which increases in TMAO concentrations have been 
observed [10]. Interestingly, however, our study did reveal 
modest negative correlations between choline levels and 
eGFR values, which is in line with results from previ-
ous studies in individuals undergoing angiography and 
patients with renal failure [10, 37]. There were no asso-
ciations between TMAO and its precursors with routine 
biomarkers of glucose metabolism, lipid metabolism and 
inflammation in the present study. While correlations of 
TMAO with HbA1c, LDL, triglycerides and CRP may have 
been expected in consideration of experimental findings 
[3, 38], our results are consistent with those of previous 
epidemiological studies [33]. Again, we cannot rule out 
that the lack of correlations between TMAO, its precur-
sors and routine biomarkers in the EPIC-Heidelberg 
study is related to the good overall health status of our 
participants.
Our study was the first to evaluate the intra- individual 
variation of TMAO, betaine in choline over 1 year in a 
general population of adults. While admittedly the dietary 
determinants of blood concentrations of TMAO and its 
metabolites could not be analyzed in a controlled manner, 
we believe that our study was appropriate to evaluate the 
biological reproducibility of metabolite levels in a real-
world setting. Nevertheless, we have to acknowledge that 
we could not address the role of changes in the intestinal 
microbiome, which may underlie the observed variation 
in TMAO levels and thus deserve further study.
Conclusions
In summary, we observed a good biological reproducibil-
ity of choline and particularly betaine concentrations over 
1 year in fasting blood samples of adults aged 47–80 years 
without diagnosed cancer or major renal and CVD. By con-
trast, TMAO concentrations showed clear intra-individual 
variation over time, driven by a greater within-person 
than between-person variation, which may speak against 
the use of TMAO as a risk marker in epidemiological long-
term studies. The causes underlying the variation in TMAO 
levels remain to be clarified in future studies.
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